Summary Twenty-six patients with relapsed or drug-resistant cancer were treated with a combination of oral etoposide (300 mg day-' for 3 days) and high-dose oral tamoxifen as a potential modulator of drug resistance (480 or 720mgday-' for 6 days beginning 3 days before etoposide). One patient with relapsed high-grade lymphoma and one with adenocarcinoma of unknown primary site has a partial response. Toxicity consisting of nausea, vomiting and subjective dizziness, unsteadiness of gait and malaise occurred during tamoxifen treatment. Serum levels of tamoxifen averaged 3-3.5 gM on day 4 of all courses of treatment at both 480 and 720 mg day-'. N-desmethyltamoxifen levels were lower than tamoxifen during the first course (2 JM) but increased to equal tamoxifen levels during the second course. Didesmethyltamoxifen levels remained below 1 gM. In vitro, both tamoxifen and the standard modulator of multidrug resistance, verapamil, produced minor enhancement of etoposide cytotoxicity in the MCF-7 wt cell line but produced no enhancement with any other cell line. High, intermittent doses of tamoxifen can be given with acceptable toxicity and produce serum levels that have been shown to modulate drug resistance in vitro. In vitro, however, such levels have no significant effect on etoposide cytotoxicity towards a range of wild-type and MDR cell lines.
Cytotoxic drug resistance frequently affects a wide range of cytotoxic agents. It is commonly inherent, although it may also be acquired after initial response to cytotoxic drugs. Cell lines exposed in vitro to one cytotoxic drug may also become resistant to a range of structurally and functionally diverse agents. This multidrug resistant (MDR) phenotype is associated with the presence of a 170 kd membrane glycoprotein, the P-glycoprotein (Pgp) (Juliano et al., 1976; Kartner et al., 1983; Riordan et al., 1985) which acts as an energy dependent efflux pump (Skovsgaard, 1978) . Many compounds have been shown to inhibit the action of Pgp thereby partly or completely overcoming drug resistance. Such resistance modifiers include verapamil (Tsuruo et al., 1981) and other calcium antagonists, phenothiazines ) and cyclosporin A (Nooter et al., 1989) .
Many studies have attempted to reproduce the resistance modifying action of these drugs in a clinical setting. Unfortunately many cause unacceptable toxicity at levels below those needed to modulate resistance and have therefore not been useful clinically (Ozols et al., 1987) . Some encouraging results have however been reported in lymphoid malignancies. Verapamil and cyclosporin A appear to be able to reverse clinical drug resistance in myeloma and acute myelocytic leukaemia respectively (Dalton et al., 1989; Nooter et al., 1989) .
The anti-oestrogen tamoxifen is one of the compounds that can modify multidrug resistance (Chatterjee et al., 1990b) . It is widely used in the treatment of breast cancer at doses of 20-40mgday-' and at such doses produces serum levels around 0.5 JiM (Adam et al., 1980; Fabian et al., 1980; Lien et al., 1989) . Doses up to 100mgday-' have however been used with little toxicity, except for retinal toxicity after continuous treatment for periods of longer than 12 months (Kaiser-Kupfer et al., 1978) . High doses of tamoxifen may thus have the potential to produce serum levels sufficient to modulate multidrug resistance in vitro (3-10JAM) (Chatterjee et al., 1990b; Foster et al., 1988; Ramu et al., 1984) making it an interesting compound to assess as a modifier of clinical drug resistance.
Etoposide (VP16-213, Vepesid) is an epipodophyllotoxin derived cytotoxic drug which interferes with the action of the nuclear enzyme topoisomerase II producing lethal single and double stranded DNA breaks (Chen et al., 1984) . It has activity in a number of solid tumours and resistance to it is part of the typical MDR phenotype (Endicott et al., 1989) . Etoposide is active orally and has manageable toxicity making it an attractive agent to combine with tamoxifen to produce an out-patient regimen.
We have therefore untaken a clinical study of oral etoposide in combination with intermittent, high-dose tamoxifen. This study has the dual aims of determining the maximum serum levels of tamoxifen and its metabolites that could be achieved and of assessing the toxicity and feasibility of the drug combination. The study therefore Study protocol Treatment comprised high-dose oral tamoxifen combined with oral etoposide. Tamoxifen was given on days 1 to 6, etoposide on days 4 to 6 and treatment was repeated each 3 weeks. We have previously used tamoxifen at a dose of 320 mg day-' for 6 days (Millward et al., 1992) and in this study the first nine patients received 480 mg day-'. As no dose-limiting toxicity was noted the subsequent 16 patients received 720mg day-' (12 20mg tablets, three times day-').
No formal compliance check was conducted but patients were asked specifically whether they had difficulties taking the correct number of tablets. Oral Determination of levels of tamoxifen and its metabolites Levels of tamoxifen and its metabolites were measured using high-performance liquid chromatography. The methods used have been published previously (Lien et al., 1989; 1987) . Briefly, tamoxifen and its metabolites were determined in the acetonitrile extract from serum and were separated by reverse-phase, low-dispersion, liquid chromatography. The drugs were detected by being converted to fluorophors by subjecting the effluent of the column to ultra-violet light while passing through a quartz tube. The identity of the analyses was confirmed by liquid chromatography/mass spectrometry using an on-line mass spectrometer connected to the analytical column (Lien et al., 1988) . Serum levels in different patient populations were compared using the Mann-Whitney U-test.
Cells and culture conditions Three pairs of cell lines were assessed. Each comprised a wild-type parental cell line and a P-glycoprotein expressing daughter line. The wild-type MCF-7 cell line was derived from a human breast cancer (Soule et al., 1973) while the CHO-KI cell line was derived from Chinese hamster ovaries (CHO). The doxorubicin hydrochloride (dox)-resistant daughter lines of each (MCF-7 adrr and CHO-KI adrr respectively) were developed by stepwise exposure to increasing dox concentrations (Batist et al., 1986; Chatterjee et al., 1990a) . Both express Pgp and have a typical MDR phenotype. The SI cell line (also known as SW-1573) was isolated from a human squamous cell lung cancer by Dr Leibovitz (Scott and White Clinic, Temple, TX). Its resistant offspring (S1/1.1) was produced by F. Baas (Neurozintuigenlab K2-214, 1105 AZ Amsterdam) by transfecting the Sl cell line with an expression vector (PFRCMV mdrl) bearing a full-length cDNA of the human mdrl gene isolated from human liver using previously described methods (Lincke et al., 1990) . mdrl expression in the S1/1.1 cell line is at least 100 fold higher than in the S1 line (F. Baas, personal communication) while mdrl mRNA levels are about 5-fold higher than in the highly resistant 1R500 cell line produced from SWi573 by stepwise exposure to dox (Baas et al., 1990) .
Cell lines were grown at 37°C under 5% CO2 in either RPMI 1640 (human cells) or Ham's F12 (CHO cells) medium, each supplemented with 10% foetal bovine serum and 2 mM glutamine. All cell lines were regularly subcultured to maintain them in exponential growth phase and were regularly tested to ensure they were free of mycoplasma infection.
Drugs Etoposide (vepesid, VP16-213) formulated for intravenous, clinical use (Bristol-Myers Oncology, Slough, UK) was used in all experiments. Stock solutions as supplied by the manufacturers (20mgml-', 34mM) was diluted in PBS to final concentration. Tamoxifen (supplied by ICI Pharmaceuticals PLC, Macclesfield, UK) and verapamil (Sigma Chemicals, Poole) were prepared as stock solutions at 50 mM in absolute ethanol and were stored at 4°C. Dilution to final concentration were made in PBS.
Drug sensitivity assay The semi-automated, colorimetric, MTT assay was used to assess drug sensitivity (Carmichael et al., 1987) . Cells in exponential growth-phase were harvested by trypsinisation and seeded into 96-well plates in 180il fresh medium. The number of cells seeded varied from 2,000 to 8,000, according to the cell line, and was such that the control well was non-confluent at the end of the 4 day experiment. Drugs were added in a volume of 10 il (PBS alone in control wells) to give a final volume of 200 ltl. Cells were incubated for 4 days at 37°C under 5% CO2. MTT was then added (50 IL of 2 mg ml1' = 0.1 mg), the cells incubated for a further 4 h and the medium removed by inverting the plate. The formazan crystals were then dissolved in 100 ytL DMSO plus 25 IlI glycine buffer pH 10.5 (Plumb et al., 1989 
Results

Clinical results
Twenty-six patients were studied and their characteristics are listed in Table I . Median age was 50, median performance score 1. A range of histological tumour types were included with the dominant types being renal cell carcinoma (n = 6), gastrointestinal adenocarcinoma (n = 4), adenocarcinoma of unknown primary site (n = 4) and breast carcinoma (n = 3). Nine patients had received previous chemotherapy.
Response Two patients showed a partial response. One had intermediate grade lymphoma which had previously responded to combination chemotherapy including dox, cyclophosphamide and vincristine while the other had previously untreated adenocarcinoma of unknown primary site. Three patients had static disease for 24, 28 and 39 weeks, 16 patients showed no response and five patients died within two courses of treatment.
Toxicity The toxicity of the regimen is summarised in Table  II . Nausea or vomiting occurred in four of 27 (15%) courses assessed at 480mg day-' tamoxifen and in 10 of 30 (33%) courses assessed at 720 mg day'-. Significant nausea was most commonly associated with the tamoxifen treatment and generally commenced before the etoposide therapy. A number of patients experienced subjective neurological symptoms. These were ill defined and were described as 'dizziness', unsteadiness of gait or marked malaise. These symptoms did not match standard WHO toxicity categories and were graded as mild (minimal symptoms), moderate (significant symptoms not requiring action), severe (significant symptoms requiring intervention) or very severe (unable to continue treatment). No objective neurological signs were noted. These 
Discussion
We report here both clinical and in vitro studies of the effects of tamoxifen on etoposide cytotoxicity and also the serum levels of tamoxifen and its metabolites that can be achieved with intermittent high-dose tamoxifen. The clinical study assessed a range of solid tumours and showed two responses among 26 patients (in relapsed lymphoma and in untreated adenocarcinoma). As this was a phase I study designed to assess the feasibility of administering the combination of drugs it is not possible to determine the contribution of the tamoxifen to these responses as both tumour types can respond to etoposide alone. Treatment toxicity was generally manageable and was less marked than that reported with 480 mg day-' continuously (Stuart et al., 1991) . Nevertheless, we consider that 720 mg day-' is the maximum tolerated dose for tamoxifen given by this schedule. Thirty-three percent of courses at 720 mg day-' were associated with nausea or vomiting although no patient stopped treatment because of this. Neurological toxicity occurred in a number of patients taking both 480 and 720 mg day-' and comprised the same subjective symptoms noted by us in patients taking 480mg day-' continuously (Stuart et al., 1991) as well as by others (Trump et al., 1991 (Lien et al., 1991) . They showed that brain levels are some 46-fold higher than serum levels. Although the distribution of tamoxifen at high doses may be different from the standard doses assessed by Lien et al., it is likely that brain levels are considerably higher than the serum levels reported in the present study. It is also possible that tamoxifen alters the tissue distribution of etoposide rendering it more neurotoxic. The possibility that resistance modifiers may exacerbate the normal tissue toxicity of chemotherapy has been raised by one non-randomised study (Berd et al., 1991) . The extent of myelosuppression observed in this study was similar to that expected.
Several studies have described the pharmacokinetics of standard dose tamoxifen (20-40 mg day-') and the levels of its metabolites that result (Adam et al., 1980; Fabian et al., 1980; Lien et al., 1989) . These studies show steady state serum levels of tamoxifen of around 0.25-1.0IJM after 4 weeks. NDMTx accumulated more slowly to levels some 50% higher after 8 weeks. diDMTx levels are generally about 60-85% lower than those of the parent compound. These ratios are similar to those in the present study but the levels produced by high-dose therapy are lower than expected, indicating non-linear pharmacokinetics. The fact that serum levels were not significantly higher after 720 mg day-' than Values represent mean value of at least three experiments. Values represent mean value of at least three experiments.
after 480 mg day-' supports this. Non-linear pharmacokinetics may be due to lower bioavailability of high oral doses or to saturation of portal vein plasma proteins leading to increased hepatic, pre-systemic metabolism. However, patients on the higher dose were asked to take 36 tablets each day and it is possible that compliance was incomplete. We cannot exclude the possibility that the apparent non-linear pharmacokinetics were due, in part, to failure of patients to take the full dose. Tamoxifen also has a very high volume of distribution (Lien et al., 1989 ) and higher doses may have produced increased drug influx into the tissues. Blood sampling took place 1 to 4 h after treatment but did not necessarily coincide with peak levels. The influx into tissues may have been promoted by peak serum levels higher than those recorded. The greater toxicity of higher doses suggests that they produce higher levels in some tissues even though serum levels were similar. The slower fall in levels of NDMTx and diDMTx while not taking tamoxifen, and the accumulation with subsequent courses is consistent with previous reports of the longer half-life of these compounds (Adam, 1981; Lien et al., 1987) . The finding of non-linear pharmacokinetics is of clinical relevance in that it limits the ability to achieve high serum levels. A dose of 720 mg day-' for 3 days produces levels no higher than 480 mg day-' (about 3 JAM) while continuing 480 mg day-' indefinitely raises levels only marginally to around 4 gM (Stuart et al., 1991) . Trump et al. have reported somewhat higher serum levels of both tamoxifen (6.1 gM) and NDMTx (6.6 JAM) after 9 days on 260 mg of tamoxifen twice a day (Trump et al., 1991) . Full pharmacokinetics were though, not reported, so it is difficult to relate these findings to the present study. Trump et al. used more prolonged treatment and reported serum levels on day 9 to 13. We have previously shown that when taking 160 mg three times a day serum levels of tamoxifen plateau at around 4 JAM after 10 days while levels of NDMTx reach 7 AM after 21 days (Stuart et al., 1991) . Levels would therefore be expected to be higher on day 9 to 13 than on day 4, as in the present study. Timing of serum samples in relation to peak levels may be important as may differences in methodology -Trump et al. give no details of their methodology. Their report is however, consistent with the results of the present study and supports the non-linear pharmacokinetics of tamoxifen.
The in vitro studies reported here show that neither tamoxifen nor verapamil has a major effect on etoposide cytotoxicity in the cell lines assessed. Tamoxifen produced a statistically significant enhancement of etoposide cytotoxicity in the MCF-7 wt cell line and had the opposite effect in the MCF-7 adr4 line while verapamil produced similar effects. These changes were, however, modest in extent (maximum enhancement 1.9-fold) and too small to be of any clinical significance. Previous reports have shown that tamoxifen can reverse drug resistance in a number of in vitro models but these have mainly assessed adriamycin cytotoxicity. Our group has reported that tamoxifen enhances dox cytotoxicity in the MCF-7 adrr cell line and has similar effects on vinblastine cytotoxicity in the S1/1.1 and CHO-KI adrr (Kirk et al., 1991 #117; Kirk, 1992;  in press). Ramu et al. initially assessed the effects of a range of triparanol compounds, including tamoxifen, on adriamycin cytotoxicity towards the P388 murine leukaemia line and its adriamycin resistant subline (P388/ADR) (Ramu et al., 1984) . They showed that 3 JAM tamoxifen partially reversed the resistance of the P388/ADR line. Foster et al. assessed both adriamycin and vinblastine cytotoxicity in the MCF-7 adrr cell line used in the present study and also showed partial reversal in the presence of 10 gM tamoxifen (Foster et al., 1988) . The effect of tamoxifen on dox cytotoxicity towards the CHO-KI and CHO-KI adrr cell lines has also been assessed by Chatterjee and Harris who have shown enhancement of cytotoxicity in both the parental (4.8-fold) and dox resistant lines (16-fold) (Chatterjee et al., 1 990b) . Other reports confirm the resistance modifying effects of tamoxifen (Berman et al., 1991) but none have assessed its effects on etoposide cytotoxicity.
The mechanism whereby tamoxifen modified dox and vinblastine cytotoxicity is not known. Tamoxifen does not appear to bind to Pgp (Kessel, 1986) but it does inhibit both calmodulin (Tsuruo et al., 1983) and protein kinase C (Horgan et al., 1986 (Lincke et al., 1990) . The S1 parental cell line used in the present study was transfected with the same gene but has much higher inherent resitance than the parental BRO cell line (IC50 for etoposide; S1 = 3 JAM, BRO = 0.016 gM). In the S1/1.1 cell line other resistance mechanisms are likely to be present explaining the lack of effect of verapamil. Certain of these mechanisms may themselves be potential targets for modification. Changes in topoisomerase II, in site of activity of etoposide, may account for certain patterns of drug resistance. Low levels of topoisomerase expression have been related to etoposide (Kim et al., 1992) as well as to drugs with other sites of action (Giaccone et al., 1992) . Phosphorylation of topoisomerase II can also enhance resistance to etoposide (Devore et al., 1992) and would be a potential route of modulation of drug resistance.
The clinical study reported here shows that tamoxifen at a dose of either 480 mg day-' or 720 mg day-' can achieve, by the 4th day, serum levels of tamoxifen sufficient to modulate drug resistance in other in vitro models. When given for up to 6 days such doses produce acceptable toxicity. The value of tamoxifen as an in vivo modulator of drug resistance therefore deserves further study. For clinical studies we recommend intermittent high-doses of tamoxifen (480 mg day-') combined with cytotoxic drugs whose toxicity is significantly modulated in vitro. Compounds related to tamo-xifen such as toremifene also need to be assessed in this context. Toremifene can be administered at higher doses than tamoxifen (Kohler et al., 1990; Robinson et al., 1990 ) and higher serum levels can be achieved (DeGregorio et al., 1989; Kaye, 1990) . It is also an effective enhancer of drug toxicity in MDR-positive cell lines (Kirk, 1992; in press ). The in vitro data show that, although etoposide resistance is an accepted part of the MDR phenotype, this resistance is not affected by tamoxifen or verapamil which are effective modulators of the cytotoxicity of other drugs that are part of the MDR phenotype. Other studies however, show that novel modulators such as cyclosporin analogues may have a much greater effect on etoposide cytotoxicity (Gaveriaux et al., 1991) . Future clinical studies using modifiers of multidrug resistance need to select cytotoxic drugs that have been shown to be modulated in vitro by the modifier being assessed. The combination of etoposide and tamoxifen is a poor candidate for such studies.
